Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Consensus molecular subtypes classification of colorectal adenomas.

Komor MA, Bosch LJ, Bounova G, Bolijn AS, van-Diemen PD, Rausch C, Hoogstrate Y, Stubbs AP, de Jong M, Jenster G, van Grieken NC, Carvalho B, Wessels LF, Jimenez CR, Fijneman RJ, Meijer GA; NGS-ProToCol Consortium, Dits N, Böttcher R, Hiemstra AC, Ylstra B, Sie D, van den Broek E, van der Meer D, Pepers F, Caldenhoven E, Janssen B, van Workum W, van Lieshout S, Bangma CH, van Leenders G, van de Werken H.

J Pathol. 2018 Jul 3. doi: 10.1002/path.5129. [Epub ahead of print]

PMID:
29968252
2.

Epithelial-mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression.

Kolijn K, Verhoef EI, Smid M, Böttcher R, Jenster GW, Debets R, van Leenders GJ.

Cancer Res. 2018 Jun 19. pii: canres.3752.2017. doi: 10.1158/0008-5472.CAN-17-3752. [Epub ahead of print]

PMID:
29921693
3.

Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures.

Guggenberger F, van de Werken HJG, Erb HHH, Cappellano G, Trattnig K, Handle F, Peer S, Schäfer G, Jenster G, Culig Z, Skvortsova I, Santer FR.

Eur Urol. 2018 Jun 15. pii: S0302-2838(18)30427-5. doi: 10.1016/j.eururo.2018.06.002. [Epub ahead of print] No abstract available.

PMID:
29914715
4.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z.

Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.

5.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Dominguez MG, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA; Profile Study, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA.

Nat Genet. 2018 Jun 11. doi: 10.1038/s41588-018-0142-8. [Epub ahead of print]

PMID:
29892016
6.

SNPitty: An Intuitive Web Application for Interactive B-Allele Frequency and Copy Number Visualization of Next-Generation Sequencing Data.

van Riet J, Krol NMG, Atmodimedjo PN, Brosens E, van IJcken WFJ, Jansen MPHM, Martens JWM, Looijenga LH, Jenster G, Dubbink HJ, Dinjens WNM, van de Werken HJG.

J Mol Diagn. 2018 Mar;20(2):166-176. doi: 10.1016/j.jmoldx.2017.11.011. Epub 2018 Jan 2.

PMID:
29305224
7.

Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.

Böttcher R, Kweldam CF, Livingstone J, Lalonde E, Yamaguchi TN, Huang V, Yousif F, Fraser M, Bristow RG, van der Kwast T, Boutros PC, Jenster G, van Leenders GJLH.

BMC Cancer. 2018 Jan 2;18(1):8. doi: 10.1186/s12885-017-3976-z.

8.

Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling.

El-Sayed IY, Daher A, Destouches D, Firlej V, Kostallari E, Maillé P, Huet E, Haidar-Ahmad N, Jenster G, de la Taille A, Abou Merhi R, Terry S, Vacherot F.

Cancer Lett. 2017 Dec 1;410:100-111. doi: 10.1016/j.canlet.2017.09.010. Epub 2017 Sep 19.

PMID:
28935391
9.

Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.

Soekmadji C, Corcoran NM, Oleinikova I, Jovanovic L; Australian Prostate Cancer Collaboration BioResource, Ramm GA, Nelson CC, Jenster G, Russell PJ.

Prostate. 2017 Oct;77(14):1416-1423. doi: 10.1002/pros.23403. Epub 2017 Aug 29. Review.

PMID:
28856701
10.

Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.

Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R.

Eur Urol. 2018 Jan;73(1):e11-e12. doi: 10.1016/j.eururo.2017.07.034. Epub 2017 Aug 9. No abstract available.

PMID:
28801127
11.

Integration of EGA secure data access into Galaxy.

Hoogstrate Y, Zhang C, Senf A, Bijlard J, Hiltemann S, van Enckevort D, Repo S, Heringa J, Jenster G, J A Fijneman R, Boiten JW, A Meijer G, Stubbs A, Rambla J, Spalding D, Abeln S.

F1000Res. 2016 Dec 12;5. pii: ELIXIR-2841. doi: 10.12688/f1000research.10221.1. eCollection 2016.

12.

A mononucleotide repeat in PRRT2 is an important, frequent target of mismatch repair deficiency in cancer.

Alves IT, Cano D, Böttcher R, van der Korput H, Dinjens W, Jenster G, Trapman J.

Oncotarget. 2017 Jan 24;8(4):6043-6056. doi: 10.18632/oncotarget.13464.

13.

Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer.

Hoogland AM, Böttcher R, Verhoef E, Jenster G, van Leenders GJ.

Oncotarget. 2016 Jun 21;7(25):37846-37856. doi: 10.18632/oncotarget.9344.

14.

The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.

Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R.

Eur Urol. 2017 Apr;71(4):680-687. doi: 10.1016/j.eururo.2016.08.012. Epub 2016 Oct 10.

PMID:
27733296
15.

Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.

Böttcher R, Dulla K, van Strijp D, Dits N, Verhoef EI, Baillie GS, van Leenders GJ, Houslay MD, Jenster G, Hoffmann R.

Oncotarget. 2016 Oct 25;7(43):70669-70684. doi: 10.18632/oncotarget.12204.

16.

DNA integrity as biomarker in pancreatic cyst fluid.

Utomo WK, Janmaat VT, Verhaar AP, Cros J, Lévy P, Ruszniewski P, den Berg MS, Jenster G, Bruno MJ, Braat H, Fuhler GM, Peppelenbosch MP.

Am J Cancer Res. 2016 Aug 1;6(8):1837-41. eCollection 2016.

17.

mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.

Stelloo S, Sanders J, Nevedomskaya E, de Jong J, Peters D, van Leenders GJ, Jenster G, Bergman AM, Zwart W.

Oncotarget. 2016 May 31;7(22):32916-24. doi: 10.18632/oncotarget.8767.

18.

A comprehensive repertoire of tRNA-derived fragments in prostate cancer.

Olvedy M, Scaravilli M, Hoogstrate Y, Visakorpi T, Jenster G, Martens-Uzunova ES.

Oncotarget. 2016 Apr 26;7(17):24766-77. doi: 10.18632/oncotarget.8293.

19.

Extracellular Vesicles and Their Role in Urologic Malignancies.

Junker K, Heinzelmann J, Beckham C, Ochiya T, Jenster G.

Eur Urol. 2016 Aug;70(2):323-31. doi: 10.1016/j.eururo.2016.02.046. Epub 2016 Feb 28. Review.

PMID:
26924769
20.

An immunoassay for urinary extracellular vesicles.

Salih M, Fenton RA, Knipscheer J, Janssen JW, Vredenbregt-van den Berg MS, Jenster G, Zietse R, Hoorn EJ.

Am J Physiol Renal Physiol. 2016 Apr 15;310(8):F796-F801. doi: 10.1152/ajprenal.00463.2015. Epub 2016 Jan 28.

21.

The Potential of MicroRNAs as Prostate Cancer Biomarkers.

Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, Visakorpi T, Calin GA.

Eur Urol. 2016 Aug;70(2):312-22. doi: 10.1016/j.eururo.2015.12.054. Epub 2016 Jan 22. Review.

22.

FuMa: reporting overlap in RNA-seq detected fusion genes.

Hoogstrate Y, Böttcher R, Hiltemann S, van der Spek PJ, Jenster G, Stubbs AP.

Bioinformatics. 2016 Apr 15;32(8):1226-8. doi: 10.1093/bioinformatics/btv721. Epub 2015 Dec 10.

PMID:
26656567
23.

Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression.

Böttcher R, Henderson DJ, Dulla K, van Strijp D, Waanders LF, Tevz G, Lehman ML, Merkle D, van Leenders GJ, Baillie GS, Jenster G, Houslay MD, Hoffmann R.

Br J Cancer. 2015 Nov 17;113(10):1502-11. doi: 10.1038/bjc.2015.335.

24.

Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects.

Salman JW, Schoots IG, Carlsson SV, Jenster G, Roobol MJ.

Adv Exp Med Biol. 2015;867:93-114. doi: 10.1007/978-94-017-7215-0_7. Review.

PMID:
26530362
25.

Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor Tissue.

Aakula A, Kohonen P, Leivonen SK, Mäkelä R, Hintsanen P, Mpindi JP, Martens-Uzunova E, Aittokallio T, Jenster G, Perälä M, Kallioniemi O, Östling P.

Eur Urol. 2016 Jun;69(6):1120-8. doi: 10.1016/j.eururo.2015.09.019. Epub 2015 Oct 20.

PMID:
26489476
26.

Androgen receptor profiling predicts prostate cancer outcome.

Stelloo S, Nevedomskaya E, van der Poel HG, de Jong J, van Leenders GJ, Jenster G, Wessels LF, Bergman AM, Zwart W.

EMBO Mol Med. 2015 Nov;7(11):1450-64. doi: 10.15252/emmm.201505424.

27.

Discriminating somatic and germline mutations in tumor DNA samples without matching normals.

Hiltemann S, Jenster G, Trapman J, van der Spek P, Stubbs A.

Genome Res. 2015 Sep;25(9):1382-90. doi: 10.1101/gr.183053.114. Epub 2015 Jul 24.

28.

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S.

Eur Urol. 2015 Dec;68(6):939-45. doi: 10.1016/j.eururo.2015.07.007. Epub 2015 Jul 15.

PMID:
26188394
29.

Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential.

Ruela-de-Sousa RR, Hoekstra E, Hoogland AM, Souza Queiroz KC, Peppelenbosch MP, Stubbs AP, Pelizzaro-Rocha K, van Leenders GJLH, Jenster G, Aoyama H, Ferreira CV, Fuhler GM.

Eur Urol. 2016 Apr;69(4):710-719. doi: 10.1016/j.eururo.2015.06.040. Epub 2015 Jul 7.

PMID:
26159288
30.

Immuno-based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer.

Duijvesz D, Versluis CY, van der Fels CA, Vredenbregt-van den Berg MS, Leivo J, Peltola MT, Bangma CH, Pettersson KS, Jenster G.

Int J Cancer. 2015 Dec 15;137(12):2869-78. doi: 10.1002/ijc.29664. Epub 2015 Jul 16.

31.

C/D-box snoRNA-derived RNA production is associated with malignant transformation and metastatic progression in prostate cancer.

Martens-Uzunova ES, Hoogstrate Y, Kalsbeek A, Pigmans B, Vredenbregt-van den Berg M, Dits N, Nielsen SJ, Baker A, Visakorpi T, Bangma C, Jenster G.

Oncotarget. 2015 Jul 10;6(19):17430-44.

32.

MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2.

Scaravilli M, Porkka KP, Brofeldt A, Annala M, Tammela TL, Jenster GW, Nykter M, Visakorpi T.

Prostate. 2015 Jun;75(8):798-805. doi: 10.1002/pros.22961. Epub 2015 Mar 1.

PMID:
25731699
33.

Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer.

Böttcher R, Hoogland AM, Dits N, Verhoef EI, Kweldam C, Waranecki P, Bangma CH, van Leenders GJ, Jenster G.

Oncotarget. 2015 Feb 28;6(6):4036-50.

34.

Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy.

Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A.

Int J Mol Sci. 2015 Feb 11;16(2):3856-69. doi: 10.3390/ijms16023856.

35.

Identification and diagnostic performance of a small RNA within the PCA3 and BMCC1 gene locus that potentially targets mRNA.

Drayton RM, Rehman I, Clarke R, Zhao Z, Pang K, Miah S, Stoehr R, Hartmann A, Blizard S, Lavin M, Bryant HE, Martens-Uzunova ES, Jenster G, Hamdy FC, Gardiner RA, Catto JW.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):268-75. doi: 10.1158/1055-9965.EPI-14-0377. Epub 2014 Nov 12.

36.

SYK is a candidate kinase target for the treatment of advanced prostate cancer.

Ghotra VP, He S, van der Horst G, Nijhoff S, de Bont H, Lekkerkerker A, Janssen R, Jenster G, van Leenders GJ, Hoogland AM, Verhoef EI, Baranski Z, Xiong J, van de Water B, van der Pluijm G, Snaar-Jagalska BE, Danen EH.

Cancer Res. 2015 Jan 1;75(1):230-40. doi: 10.1158/0008-5472.CAN-14-0629. Epub 2014 Nov 11.

37.

iReport: a generalised Galaxy solution for integrated experimental reporting.

Hiltemann S, Hoogstrate Y, der Spek Pv, Jenster G, Stubbs A.

Gigascience. 2014 Oct 13;3:19. doi: 10.1186/2047-217X-3-19. eCollection 2014.

38.

FlaiMapper: computational annotation of small ncRNA-derived fragments using RNA-seq high-throughput data.

Hoogstrate Y, Jenster G, Martens-Uzunova ES.

Bioinformatics. 2015 Mar 1;31(5):665-73. doi: 10.1093/bioinformatics/btu696. Epub 2014 Oct 22.

PMID:
25338717
39.

Serum kynurenine/tryptophan ratio is not a potential marker for detecting prostate cancer.

Rodríguez-Blanco G, Burgers PC, Dekker LJ, Vredenbregt-van den Berg MS, Ijzermans JN, Schenk-Braat EA, Jenster G, Luider TM.

Clin Biochem. 2014 Sep;47(13-14):1347-8. doi: 10.1016/j.clinbiochem.2014.05.001. Epub 2014 May 13. No abstract available.

PMID:
24833358
40.

The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells.

Henderson DJ, Byrne A, Dulla K, Jenster G, Hoffmann R, Baillie GS, Houslay MD.

Br J Cancer. 2014 Mar 4;110(5):1278-87. doi: 10.1038/bjc.2014.22. Epub 2014 Feb 11.

41.

Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer.

Teles Alves I, Hartjes T, McClellan E, Hiltemann S, Böttcher R, Dits N, Temanni MR, Janssen B, van Workum W, van der Spek P, Stubbs A, de Klein A, Eussen B, Trapman J, Jenster G.

Oncogene. 2015 Jan 29;34(5):568-77. doi: 10.1038/onc.2013.591. Epub 2014 Feb 3.

PMID:
24488012
42.

CGtag: complete genomics toolkit and annotation in a cloud-based Galaxy.

Hiltemann S, Mei H, de Hollander M, Palli I, van der Spek P, Jenster G, Stubbs A.

Gigascience. 2014 Jan 24;3(1):1. doi: 10.1186/2047-217X-3-1.

43.

Serum levels of arachidonic acid metabolites change during prostate cancer progression.

Rodríguez-Blanco G, Burgers PC, Dekker LJ, Ijzermans JJ, Wildhagen MF, Schenk-Braat EA, Bangma CH, Jenster G, Luider TM.

Prostate. 2014 May;74(6):618-27. doi: 10.1002/pros.22779. Epub 2014 Jan 16.

PMID:
24435810
44.

Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer.

Duijvesz D, Burnum-Johnson KE, Gritsenko MA, Hoogland AM, Vredenbregt-van den Berg MS, Willemsen R, Luider T, Paša-Tolić L, Jenster G.

PLoS One. 2013 Dec 31;8(12):e82589. doi: 10.1371/journal.pone.0082589. eCollection 2013.

45.

Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease.

Hoogland AM, Verhoef EI, Roobol MJ, Schröder FH, Wildhagen MF, van der Kwast TH, Jenster G, van Leenders GJ.

Prostate. 2014 May;74(5):488-96. doi: 10.1002/pros.22768. Epub 2013 Dec 27.

PMID:
24375374
46.

Long noncoding RNA in prostate, bladder, and kidney cancer.

Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T, Calin GA.

Eur Urol. 2014 Jun;65(6):1140-51. doi: 10.1016/j.eururo.2013.12.003. Epub 2013 Dec 14. Review.

PMID:
24373479
47.

SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer.

Iglesias-Gato D, Chuan YC, Wikström P, Augsten S, Jiang N, Niu Y, Seipel A, Danneman D, Vermeij M, Fernandez-Perez L, Jenster G, Egevad L, Norstedt G, Flores-Morales A.

Carcinogenesis. 2014 Jan;35(1):24-33. doi: 10.1093/carcin/bgt304. Epub 2013 Sep 12.

PMID:
24031028
48.

Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis.

Kumagai J, Hofland J, Erkens-Schulze S, Dits NF, Steenbergen J, Jenster G, Homma Y, de Jong FH, van Weerden WM.

Prostate. 2013 Nov;73(15):1636-50. doi: 10.1002/pros.22655. Epub 2013 Sep 2.

PMID:
23996639
49.

Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells.

Ramakrishnaiah V, Thumann C, Fofana I, Habersetzer F, Pan Q, de Ruiter PE, Willemsen R, Demmers JA, Stalin Raj V, Jenster G, Kwekkeboom J, Tilanus HW, Haagmans BL, Baumert TF, van der Laan LJ.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13109-13. doi: 10.1073/pnas.1221899110. Epub 2013 Jul 22.

50.

Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different?

Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A.

Int J Mol Sci. 2013 Jun 3;14(6):11816-29. doi: 10.3390/ijms140611816.

Supplemental Content

Loading ...
Support Center